Duncan GA, Lockett A, Villegas LR, Almodovar S, Gomez JL, Flores SC, Wilkes DS, Tigno XT. National Heart, Lung, and Blood Institute Workshop Summary: Enhancing Opportunities for Training and Retention of a Diverse Biomedical Workforce. Ann Am Thorac Soc. 2016 Apr;13(4):562-7. PubMed PMID: 27058184
Delaney C, Wright RH, Tang JR, Woods C, Villegas L, Sherlock L, Savani RC, Abman SH, Nozik-Grayck E. Lack of EC-SOD worsens alveolar and vascular development in a neonatal mouse model of bleomycin-induced bronchopulmonary dysplasia and pulmonary hypertension. Pediatr Res. 2015 Dec;78(6):634-40.
L. Villegas, L. Kirkbride-Romeo, J. Martinez, T. Luu, M. Le. Development of Antioxidant Peptides as a Treatment for Pulmonary Hypertension. ASP. 2015.
L. Villegas, A. Ben-Masaud, C. Woods, J. Martinez, M. Le, T. Anchordoquy, E. Nozik-Grayck. Targeted Delivery Of Protease-Resistant EC-SOD To The Pulmonary Artery. Am. J. Respir. Crit. Care Med. 2015.
Nozik-Grayck E, Woods C, Taylor JM, Benninger RK, Johnson RD, Villegas LR, Stenmark KR, Harrison DG, Majka SM, Irwin D, Farrow KN. Selective depletion of vascular EC-SOD augments chronic hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2014 Dec 1;307(11):L868-76. PubMed PMID: 25326578
Villegas L, Stidham T, Grayck E. Oxidative stress and therapeutic development in lung diseases. J. Pulmonary & Respiratory Medicine. 2014, 4:4.
L. Villegas, C. Woods, R. Johnson, R. Baid, R. Trivedi, U. Kompella, E. Nozik-Grayck. Targeted Delivery Of Protease-Resistant EC-SOD To The Pulmonary Artery. Am. J. Respir. Crit. Care Med. 2014.
Duncan G, Lockett A, Villegas LR, Almodovar S, Gomez JL, Tigno XT, Flores SC, Wilkes DS. NHLBI Workshop Summary: Enhancing Opportunities for Training and Retention of a Diverse Biomedical Workforce. Annals of the American Thoracic Society. 2015 Nov.
